Eli Lilly, InnoCare Pharma Sign Drug Research Deal Worth Up to $3.25 Billion

MT newswire2026/09/24 07:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

03:33 AM EDT, 09/24/2026 (MT Newswires) -- Eli Lilly (LLY) and InnoCare Pharma agreed to collaborate on developing new medicines targeting up to five targets, InnoCare said Thursday. Under the agreement, InnoCare said it will use its drug discovery platform to identify and develop compounds for the targets, while Lilly will support the collaboration. InnoCare is eligible to receive up to $100 million in upfront and near-term payments and about $3.25 billion in development and commercial milestone payments, the company said. It added it will also receive tiered royalties in the single digits on annual net product sales.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to data from the US Department of the Treasury, in the 12 months ending July this year, overseas investors made net purchases of US stocks totaling $942 billion, marking the highest rolling 12-month total since records began in 1985. The net purchases in the second quarter alone reached $426 billion, setting a new single-quarter record. Meanwhile, overseas demand for US Treasuries has noticeably cooled, with purchase volumes falling significantly. As a result, the US is facing higher costs in government debt financing.

华尔街见闻•2026/09/26 11:36

Analyst Gu Jingci: The market doesn't stop during the holidays. Slow movements don't mean no progress. With more patience comes greater rewards.

AiCoin•2026/09/26 11:05